Literature DB >> 16220557

Identification of 29 novel and nine recurrent fibrillin-1 (FBN1) mutations and genotype-phenotype correlations in 76 patients with Marfan syndrome.

Kathrin Rommel1, Matthias Karck, Axel Haverich, Yskert von Kodolitsch, Meike Rybczynski, Götz Müller, Krishna K Singh, Jörg Schmidtke, Mine Arslan-Kirchner.   

Abstract

Marfan syndrome (MFS) is an autosomal-dominant disorder of the fibrous connective tissue that is typically caused by mutations in the gene coding for fibrillin-1 (FBN1), a major component of extracellular microfibrils. The clinical spectrum of MFS is highly variable and includes involvement of the cardiovascular, skeletal, ocular, and other organ systems; however, the genotype-phenotype correlations have not been well developed. Various screening methods have led to the identification of about 600 different mutations (FBN1-UMD database; www.umd.be). In this study we performed SSCP and/or direct sequencing to analyze all 65 exons of the FBN1 gene in 116 patients presenting with classic MFS or related phenotypes. Twenty-nine novel and nine recurrent mutations were identified in 38 of the analyzed patients. The mutations comprised 18 missense (47%), eight nonsense (21%), and five splice site (13%) mutations. Seven further mutations (18%) resulted from deletion, insertion, or duplication events, six of which led to a frameshift and subsequent premature termination. Additionally, we describe new polymorphisms and sequence variants. On the basis of the data presented here and in a previous study, we were able to establish highly significant correlations between the FBN1 mutation type and the MFS phenotype in a group of 76 mutation-positive patients for whom comprehensive clinical data were available. Most strikingly, there was a significantly lower incidence of ectopia lentis in patients who carried a mutation that led to a premature termination codon (PTC) or a missense mutation without cysteine involvement in FBN1, as compared to patients whose mutations involved a cysteine substitution or splice site alteration. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16220557     DOI: 10.1002/humu.20239

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  31 in total

1.  Exon 47 skipping of fibrillin-1 leads preferentially to cardiovascular defects in patients with thoracic aortic aneurysms and dissections.

Authors:  Wen-Jing Wang; Peili Han; Jun Zheng; Fang-Yuan Hu; Yun Zhu; Jin-Sheng Xie; Jian Guo; Zhe Zhang; Jie Dong; Gu-Yan Zheng; Huiqing Cao; Tian-Shu Liu; Qinglin Fu; Lizhong Sun; Bi-Bo Yang; Xiao-Li Tian
Journal:  J Mol Med (Berl)       Date:  2012-07-08       Impact factor: 4.599

Review 2.  Recent progress in genetics of Marfan syndrome and Marfan-associated disorders.

Authors:  Takeshi Mizuguchi; Naomichi Matsumoto
Journal:  J Hum Genet       Date:  2006-10-24       Impact factor: 3.172

3.  Decreased frequency of FBN1 missense variants in Ghent criteria-positive Marfan syndrome and characterization of novel FBN1 variants.

Authors:  Linnea M Baudhuin; Katrina E Kotzer; Susan A Lagerstedt
Journal:  J Hum Genet       Date:  2015-02-05       Impact factor: 3.172

4.  Identification of the minimal combination of clinical features in probands for efficient mutation detection in the FBN1 gene.

Authors:  Chantal Stheneur; Gwenaëlle Collod-Béroud; Laurence Faivre; Jean François Buyck; Laurent Gouya; Jean-Marie Le Parc; Bertrand Moura; Christine Muti; Bernard Grandchamp; Gilles Sultan; Mireille Claustres; Philippe Aegerter; Bertrand Chevallier; Guillaume Jondeau; Catherine Boileau
Journal:  Eur J Hum Genet       Date:  2009-03-18       Impact factor: 4.246

5.  Large genomic fibrillin-1 (FBN1) gene deletions provide evidence for true haploinsufficiency in Marfan syndrome.

Authors:  Gábor Mátyás; Sira Alonso; Andrea Patrignani; Myriam Marti; Eliane Arnold; István Magyar; Caroline Henggeler; Thierry Carrel; Beat Steinmann; Wolfgang Berger
Journal:  Hum Genet       Date:  2007-05-10       Impact factor: 4.132

6.  Genetic Risk for Aortic Aneurysm in Adolescent Idiopathic Scoliosis.

Authors:  Gabe Haller; David M Alvarado; Marcia C Willing; Alan C Braverman; Keith H Bridwell; Michael Kelly; Lawrence G Lenke; Scott J Luhmann; Christina A Gurnett; Matthew B Dobbs
Journal:  J Bone Joint Surg Am       Date:  2015-09-02       Impact factor: 5.284

7.  Performance of a new quantitative method for assessing dural ectasia in patients with FBN1 mutations and clinical features of Marfan syndrome.

Authors:  Bahar Söylen; Kerstin Hinz; Jana Prokein; Hartmut Becker; Jörg Schmidtke; Mine Arslan-Kirchner
Journal:  Neuroradiology       Date:  2009-02-19       Impact factor: 2.804

8.  Marfan syndrome: clinical consequences resulting from a medicolegal autopsy of a case of sudden death due to aortic rupture.

Authors:  M Klintschar; U Bilkenroth; M Arslan-Kirchner; J Schmidtke; D Stiller
Journal:  Int J Legal Med       Date:  2008-10-17       Impact factor: 2.686

9.  Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study.

Authors:  L Faivre; G Collod-Beroud; B L Loeys; A Child; C Binquet; E Gautier; B Callewaert; E Arbustini; K Mayer; M Arslan-Kirchner; A Kiotsekoglou; P Comeglio; N Marziliano; H C Dietz; D Halliday; C Beroud; C Bonithon-Kopp; M Claustres; C Muti; H Plauchu; P N Robinson; L C Adès; A Biggin; B Benetts; M Brett; K J Holman; J De Backer; P Coucke; U Francke; A De Paepe; G Jondeau; C Boileau
Journal:  Am J Hum Genet       Date:  2007-07-25       Impact factor: 11.025

10.  Rare variants in FBN1 and FBN2 are associated with severe adolescent idiopathic scoliosis.

Authors:  Jillian G Buchan; David M Alvarado; Gabe E Haller; Carlos Cruchaga; Matthew B Harms; Tianxiao Zhang; Marcia C Willing; Dorothy K Grange; Alan C Braverman; Nancy H Miller; Jose A Morcuende; Nelson Leung-Sang Tang; Tsz-Ping Lam; Bobby Kin-Wah Ng; Jack Chun-Yiu Cheng; Matthew B Dobbs; Christina A Gurnett
Journal:  Hum Mol Genet       Date:  2014-05-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.